Promising objective response rates (ORR) were observed in multiple tumor types in anti-PD-(L)1 resistant patientsAnalysis of baseline biomarker data in clear cell renal cell carcinoma (ccRCC) patients reveals a doubling
- Updated safety and efficacy results on SRK-181 will be featured in an oral presentation on Monday, June 3rd, at 1:50 p.m CDT/2:50 p.m. EDT- Company will host conference call to discuss the data on Tuesday, June 4th at
Raymond James has initiated coverage on Scholar Rock Holding (NASDAQ:SRRK), supported by the potential value with a couple of key programs utilizing selective myostatin inhibition to
Preclinical findings presented at Keystone Symposia show lean mass preservation, fat mass loss, and improved glucose metabolismScholar Rock's novel myostatin inhibitor, SRK-439, is part of its growing, industry-leading
SRK-439 is a novel selective myostatin inhibitor designed for the treatment of cardiometabolic disordersPreclinical data supports the potential of SRK-439 to preserve lean muscle mass as part of healthy weight